A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Part of paid clinical trials in Los Angeles, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07291076
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pumitamig — DRUG
    Specified dose on specified days
  • Ipilimumab — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Key Dates

Start date
Mar 16, 2026
Status verified
May 2026
Primary completion
Oct 15, 2029
Completion
Oct 14, 2031

Study Design

Enrollment
198 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1A
  • Experimental: Cohort 1B
  • Experimental: Cohort 2A
  • Experimental: Cohort 2B
  • Experimental: Cohort 2C
  • Experimental: Cohort 1A2
  • Experimental: Cohort 1B2

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to approximately 25 weeks ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (9)

FacilityCityStateZIPSite coordinators
Local Institution - 0070Los AngelesCalifornia90064
Site 0070
Local Institution - 0107ChicagoIllinois60611
Site 0107
John Theurer Cancer Center at Hackensack University Medical CenterHackensackNew Jersey07601-2191
Martin Gutierrez, Site 0103
551-996-5863
Local Institution - 0100MineolaNew York11501
Site 0100
Providence Portland Medical CenterPortlandOregon97213
Binbin Zheng, Site 0080
503-215-3878
Providence St. Vincent Medical CenterPortlandOregon97225
Binbin Zheng, Site 0111
503-215-3878
Tennessee OncologyNashvilleTennessee37203
Jeffery Russell, Site 0022
615-986-0857
Vanderbilt University Medical CenterNashvilleTennessee37232
Laura Goff, Site 0102
615-322-4967
Local Institution - 0083SeattleWashington98109-1024
Site 0083

Find similar trials in Los Angeles, CA

By research site
Local Institution - 0070· Los Angeles, CALocal Institution - 0107· Chicago, ILJohn Theurer Cancer Center at Hackensack University Medical Center· Hackensack, NJLocal Institution - 0100· Mineola, NYProvidence Portland Medical Center· Portland, ORProvidence St. Vincent Medical Center· Portland, OR

Related Studies